FDA says no to Jazz Pharma fibromyalgia drug

NEW YORK (AP) - In a story Oct. 11, The Associated Press reported that the Food and Drug Administration denied approval to JZP-6, a Jazz Pharmaceuticals drug candidate intended to treat fibromyalgia. The drug is approved under the name Xyrem as a treatment for narcolepsy and cataplexy.